David is a solicitor with experience across a variety of areas of intellectual property practice, including patents, designs, trade marks and passing off. He joined Dehns in 2022.
As a former pharmaceutical research scientist, David has a particular interest in contentious and non-contentious patent and regulatory matters affecting the life sciences sector. He has also assisted clients with patent opinions, freedom to operate and validity assessments and issues concerning pharmaceutical product lifecycle management.
David handles IP work for clients ranging from individuals and small start-up companies to major multinationals. In addition to contentious matters, David also advises on licensing and contractual agreements relating to the development and exploitation of intellectual property rights.
Prior to qualifying as a lawyer, David spent over a decade as a pharmaceutical research scientist at clinical centres in London (King’s College London), Paris (INSERM) and New York (NYU Medical Centre), before leading a neuroscience pre-clinical drug discovery team at GlaxoSmithKline.
Postgraduate Diploma in Intellectual Property Law and Practice, University of Oxford, 2017
PhD, Clinical Biochemistry, King’s College London, 1996
BSc, Biochemistry, University of Wales, 1991
David previously worked in Beijing and Hong Kong for several years and has assisted clients with enforcement strategies in China and Southeast Asia.
David was recognised as a “Notable Practitioner” in the 2023 edition of Managing Intellectual Property’s IP Stars.
Horsham Nutraceuticals Ltd & Anor v Manna Pro Products LLC [2019] EWHC 1935 (Ch)
Glew & Ors v Amro Biotech & Ors [2019] EWHC 3183 (Ch)
Icescape Ltd. V Ice-World International BV [2018] Civ 2219
Fontem Holdings 1BV v Ten Motives Ltd [2015] EWHC 2752 (Pat)
ViiV Healthcare Ltd v Teva UK Ltd [2015] EWHC 1074 (Ch)